Page 55 - IMO-2-2

Innovative Medicines & Omics Alzheimer’s disease and clinical trials

BACE1 inhibitor LY2886721 elicits robust central Aβ doi: 10.1021/acs.jmedchem.8b00246
pharmacodynamic responses in mice, dogs, and humans. 132. Jacobsen H, Ozmen L, Caruso A, et al. Combined treatment
J Neurosci. 2015;35:1199-1210.
with a BACE inhibitor and anti-Aβ antibody gantenerumab
doi: 10.1523/JNEUROSCI.4129-14.2015 enhances amyloid reduction in APPLondon mice. J Neurosci.
2014;34:11621-11630.
123. Wessels AM, Tariot PN, Zimmer JA, et al. Efficacy and
safety of lanabecestat for treatment of early and mild doi: 10.1523/JNEUROSCI.1405-14.2014
alzheimer disease: The AMARANTH and DAYBREAK-ALZ 133. Egan MF, Mukai Y, Voss T, et al. Further analyses of the
randomized clinical trials. JAMA Neurol. 2020;77:199-209. safety of verubecestat in the phase 3 EPOCH trial of mild-
doi: 10.1001/jamaneurol.2019.3988 to-moderate Alzheimer’s disease. Alzheimers Res Ther.
2019;11:68.
124. Bullich S, Mueller A, De Santi S, et al. Evaluation of tau
deposition using F-PI-2620 PET in MCI and early AD doi: 10.1186/s13195-019-0520-1
18
subjects-a MissionAD tau sub-study. Alzheimers Res Ther. 134. Egan MF, Kost J, Tariot PN, et al. Randomized trial of
2022;14:105. verubecestat for mild-to-moderate Alzheimer’s disease.
doi: 10.1186/s13195-022-01048-x N Engl J Med. 2018;378:1691-1703.

125. Sudduth TL, Greenstein A, Wilcock DM. Intracranial doi: 10.1056/NEJMoa1706441
injection of Gammagard, a human IVIg, modulates the 135. Egan MF, Kost J, Voss T, et al. Randomized trial of
inflammatory response of the brain and lowers Aβ in verubecestat for prodromal Alzheimer’s disease. N Engl J
APP/PS1 mice along a different time course than anti-Aβ Med. 2019;380:1408-1420.
antibodies. J Neurosci. 2013;33:9684-9692.
doi: 10.1056/NEJMoa1812840
doi: 10.1523/JNEUROSCI.1220-13.2013
136. Rynearson KD, Ponnusamy M, Prikhodko O, et al. Preclinical
126. Doody RS, Raman R, Farlow M, et al. A phase 3 trial of validation of a potent γ-secretase modulator for Alzheimer’s
semagacestat for treatment of Alzheimer’s disease. N Engl J disease prevention. J Exp Med. 2021;218:e20202560.
Med. 2013;369:341-350.
doi: 10.1084/jem.20202560
doi: 10.1056/NEJMoa1210951
137. Burstein AH, Sabbagh M, Andrews R, Valcarce C, Dunn I,
127. Coric V, van Dyck CH, Salloway S, et al. Safety and Altstiel L. Development of azeliragon, an oral small molecule
tolerability of the gamma-secretase inhibitor avagacestat in antagonist of the receptor for advanced glycation endproducts,
a phase 2 study of mild to moderate Alzheimer disease. Arch for the potential slowing of loss of cognition in mild Alzheimer’s
Neurol. 2012;69:1430-1440. disease. J Prev Alzheimers Dis. 2018;5:149-154.
doi: 10.1001/archneurol.2012.2194 doi: 10.14283/jpad.2018.18
128. Coric V, Salloway S, van Dyck CH, et al. Targeting prodromal 138. Pasqualetti P, Bonomini C, Dal Forno G, et al. A randomized
Alzheimer disease with avagacestat: A randomized clinical controlled study on effects of ibuprofen on cognitive
trial. JAMA Neurol. 2015;72:1324-1333. progression of Alzheimer’s disease. Aging Clin Exp Res.
doi: 10.1001/jamaneurol.2015.0607 2009;21:102-110.
129. Thakker DR, Sankaranarayanan S, Weatherspoon MR, et al. doi: 10.1007/BF03325217
Centrally delivered BACE1 inhibitor activates microglia, 139. Bareggi SR, Cornelli U. Clioquinol: Review of its mechanisms
and reverses amyloid pathology and cognitive deficit in aged of action and clinical uses in neurodegenerative disorders.
Tg2576 mice. J Neurosci. 2015;35:6931-6936. CNS Neurosci Ther. 2012;18:41-46.
doi: 10.1523/JNEUROSCI.2262-14.2015 doi: 10.1111/j.1755-5949.2010.00231.x
130. Qiu R, Ahn JE, Alexander R, et al. Safety, tolerability, 140. Cherny RA, Atwood CS, Xilinas ME, et al. Treatment with
pharmacokinetics, and pharmacodynamic effects of a copper-zinc chelator markedly and rapidly inhibits beta-
PF-06751979, a potent and selective oral BACE1 inhibitor: amyloid accumulation in Alzheimer’s disease transgenic
Results from phase I studies in healthy adults and healthy mice. Neuron. 2001;30:665-676.
older subjects. J Alzheimers Dis. 2019;71:581-595.
doi: 10.1016/s0896-6273(01)00317-8
doi: 10.3233/JAD-190228
141. Salloway S, Sperling R, Keren R, et al. A phase 2 randomized
131. O’Neill BT, Beck EM, Butler CR, et al. Design and trial of ELND005, scyllo-inositol, in mild to moderate
synthesis of clinical candidate PF-06751979: A potent, Alzheimer disease. Neurology. 2011;77:1253-1262.
brain penetrant, β-Site amyloid precursor protein cleaving
enzyme 1 (BACE1) inhibitor lacking hypopigmentation. doi: 10.1212/WNL.0b013e3182309fa5
J Med Chem. 2018;61:4476-4504. 142. Abushakra S, Porsteinsson A, Vellas B, et al. Clinical benefits

Volume 2 Issue 2 (2025) 49 doi: 10.36922/IMO025050007